FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after recei

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significan

MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals tod

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a l

On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current pri

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR New

Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underse

Amneal Pharmaceuticals NASDAQ: AMRX Co-Founder, President and Co-Chief Executive Officer Chirag Pate

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to s

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and hi

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth fro

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a p

Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients w

BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“A

Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approv

Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approv

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announc

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requ

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“A

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight

Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars pla

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversifie

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of C

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy r

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy

Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up t

Amneal Pharmaceuticals (NASDAQ:AMRX) is looking for FY2026 Adj EPS of $0.93-$1.03 vs $0.94 analyst e

Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.21 per share which beat the a

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announ

Amneal Pharmaceuticals (NASDAQ:AMRX) affirms FY2025 Adj EPS guidance from $0.75-$0.80 to $0.75-$0.80

KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodege

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) and mAbxience

Barclays analyst Glen Santangelo initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with

Interim data show substantial improvements in "Good On" time compared to other oral CD/LD th

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announ

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announc

Piper Sandler analyst David Amsellem reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overw